QIAGEN Clinical Insight

paid

QIAGEN Digital Insights offers expert-curated bioinformatics software for NGS secondary analysis, variant interpretation, pathway analysis, and clinical reporting—from research to patient care.

Data & Analytics

Research & Education

AI Research Tools

About

QIAGEN Digital Insights (formerly QIAGEN Clinical Insight) is an end-to-end bioinformatics platform designed to bridge the gap between raw genomic data and clinically or scientifically actionable decisions. The platform integrates a broad portfolio of tools spanning secondary NGS analysis, variant interpretation, pathway analysis, and enterprise-grade knowledge bases. Key products include QCI Interpret for Oncology and Hereditary Diseases, which delivers on-demand, expert-curated variant interpretation and patient-specific reports for any NGS panel within minutes. QIAGEN Ingenuity Pathway Analysis (IPA) enables researchers to analyze, compare, and contextualize NGS data through the industry-leading pathway and network analysis application. QIAGEN CLC Genomics and CLC Workbench provide powerful desktop and cloud-based secondary analysis pipelines for diverse sequencing workflows, including microbial genomics, single-cell sequencing, and metagenomics. The platform's knowledge bases—including COSMIC (Catalogue of Somatic Mutations in Cancer), HGMD (Human Gene Mutation Database), DiseaseLand, OncoLand, and the Biomedical Knowledge Base—provide access to over 640 million curated biomedical relationships and 10 million high-quality biological findings, accelerating drug discovery, biomarker identification, and target validation. QIAGEN Digital Insights holds European IVDR certification for QCI Interpret, underscoring its suitability for regulated clinical diagnostics environments. The platform is used by clinical NGS labs, translational researchers, pharmaceutical companies, and bioinformatics teams seeking scalable, expert-validated genomic intelligence from discovery through patient care.

Key Features

QCI Interpret for Oncology & Hereditary Diseases: Delivers on-demand, expert-curated variant interpretation and patient-specific clinical reports for any NGS panel in minutes, with IVDR-certified workflows.
Ingenuity Pathway Analysis (IPA): Industry-leading application for analyzing, comparing, and contextualizing NGS data through pathway, network, and upstream regulator analysis.
QIAGEN CLC Genomics Suite: Comprehensive desktop and cloud-based secondary NGS analysis tools covering whole-genome, RNA-seq, single-cell, microbial genomics, and metagenomics workflows.
Curated Biomedical Knowledge Bases: Access to 640M+ biomedical relationships, COSMIC, HGMD, DiseaseLand, OncoLand, and 700K+ preprocessed omics samples for discovery and clinical research.
OmicSoft NGS Data Exploration: Cloud-based suite to explore and compare data across 700K+ disease studies, enabling biomarker identification, target discovery, and mechanism-of-action research.

Use Cases

Clinical oncology NGS laboratories interpreting variants in solid tumor and hematological malignancy panels for patient-specific treatment recommendations.
Hereditary disease and carrier screening programs requiring fast, expert-validated variant classification and clinical report generation.
Pharmaceutical and biotech R&D teams performing biomarker discovery, target identification, and mechanism-of-action analysis across large omics datasets.
Rare and undiagnosed disease programs leveraging curated genomic knowledge bases to find molecular diagnoses where conventional testing has failed.
Translational and academic researchers performing pathway analysis, multi-omics data integration, and comparative disease study exploration using IPA and OmicSoft.

Pros

Expert-Curated, Certified Content: Variant interpretations and knowledge bases are manually curated by domain experts and backed by European IVDR certification, ensuring regulatory-grade reliability.
End-to-End NGS Coverage: A single vendor platform covers the entire NGS pipeline—from raw data secondary analysis through clinical reporting—reducing integration complexity.
Massive Biomedical Knowledge Graph: With 640M+ curated biomedical relationships and 10M+ biological findings, users can uncover novel connections and accelerate drug discovery.
Broad Clinical Application Support: Supports oncology (solid tumors, hematological malignancies), hereditary diseases, rare and undiagnosed diseases, and carrier screening in clinical lab settings.

Cons

Enterprise-Tier Pricing: Pricing is not publicly listed and is tailored to enterprise agreements, making it inaccessible for individual researchers or small labs with limited budgets.
Steep Learning Curve: The breadth of tools and modules requires significant bioinformatics expertise and onboarding time, which may be challenging for less specialized teams.
Niche Audience: The platform is purpose-built for genomics and clinical diagnostics, making it unsuitable for general data analytics or non-life-science use cases.

Frequently Asked Questions

QIAGEN Digital Insights is QIAGEN's bioinformatics software division, offering a suite of tools for NGS secondary analysis, genomic data interpretation, pathway analysis, and clinical reporting. It serves researchers, clinical labs, and pharmaceutical companies.

QCI Interpret is a cloud-based clinical variant interpretation solution available for oncology and hereditary disease testing. It is designed for clinical NGS laboratories that need to generate patient-specific, expert-curated reports efficiently and in compliance with regulatory standards.

Yes. QIAGEN has received European IVDR (In Vitro Diagnostic Regulation) certification for QCI Interpret, confirming it meets the regulatory requirements for clinical in vitro diagnostics use in Europe.

The platform includes COSMIC (Catalogue of Somatic Mutations in Cancer), HGMD (Human Gene Mutation Database), DiseaseLand, OncoLand, the Biomedical Knowledge Base with 640M+ relationships, and the OmicSoft Land Explorer with 700K+ preprocessed omics samples.

Yes. Through tools like Ingenuity Pathway Analysis, OmicSoft, and the Biomedical Knowledge Bases, the platform supports biomarker identification, target discovery, cancer drug discovery, and mechanism-of-action studies for pharmaceutical and translational research teams.